Bass, Berry & Sims attorneys John Kelly and Lindsey Fetzer authored an article for Pharmaceutical Compliance Monitor. The article outlines corruption risk areas pharmaceutical companies are often faced with when conducting business in high-risk and emerging international markets. John and Lindsey discuss the risks associated with the following:

  1. State-Owned Hospitals
  2. Foreign Clinical Trials
  3. Entertainment and Hospitality

The full article, “FCPA and the Pharmaceutical Industry: A Uniquely High-Risk Environment,” was published by Pharmaceutical Compliance Monitor on November 25, 2015 and is available online.